title: Oral Chemotherapy in Patients with Hematological Malignancies-Care Process, Pharmacoeconomic and Policy Implications.
abstract: Patients with hematologic malignancies are increasing being prescribed oral anticancer medications (OAMs) and/or biologics. These newer targeted OAMs are associated with a host of practical and pharmacoeconomic implications for patients and healthcare providers. Issues such as safety, procurement challenges, and the need for proactive involvement of all stakeholders to optimize adherence for successful use of these agents are increasingly being recognized. The current reactive model is negatively impacting the patient experience through delays in care, financial toxicity, and decreased safety. It also impacts the healthcare providers in the form of lost revenue and staff burnout due to labor-intensive procurement and patient financial assistance burdens. In this review, we describe some of the issues identified and discuss potential strategies to improve patient access, minimize healthcare burden, and review current policy initiatives and patient advocacy efforts to reduce financial toxicity.
authors.affiliation: Department of Pharmacy, Mayo Clinic, 5881 Mayo Boulevard, Phoenix, AZ, 85054, USA. betcher.jeffrey@mayo.edu.
authors.forename: Jeffrey
authors.initials: J
authors.lastname: Betcher
authors.affiliation: Department of Pharmacy, Mayo Clinic, 5881 Mayo Boulevard, Phoenix, AZ, 85054, USA.
authors.forename: Elizabeth
authors.initials: E
authors.lastname: Dow
authors.affiliation: Division of Hematology/Medical Oncology, Mayo Clinic, 5881 Mayo Boulevard, Phoenix, AZ, 85054, USA.
authors.forename: Nandita
authors.initials: N
authors.lastname: Khera
mesh_terms: D000284:Administration, Oral; D000970:Antineoplastic Agents / Q000191:economics / Q000627:therapeutic use*; D017850:Economics, Pharmaceutical; D019337:Hematologic Neoplasms / Q000188:drug therapy*; D006801:Humans; D055118:Medication Adherence; D010353:Patient Education as Topic
chemical_list: D000970:Antineoplastic Agents
keywords: Medication adherence; Oral anticancer drugs; Oral cancer therapy; Oral chemotherapy; Oral parity; Pharmacoeconomics